Knowles said it's still 'kind of shocking that such a detailed package [on terminal disclaimer] with examples of how to implement it' would be published by the Office if it wasn't confident it was going to be finalized.
Knowles kicked off the discussion with the observation that the pharmaceutical industry 'has been considered pretty close to the devil' recently, pointing to legislation like the Inflation Reduction Act (IRA) and other proposals linking patents with drug pricing.
Panelists breathed a sigh of relief that certain rule proposals considered most destructive to the industry seem unlikely to move forward, while lamenting the negative tenor of the public debate around pharmaceutical patents today.
According to Pedersen, Vidal strongly hinted during the recent American Intellectual Property Law Association (AIPLA) Annual Meeting that she will be closing out all of the controversial proposals.
#pharmaceutical-patents #regulatory-environment #public-perception #intellectual-property #life-sciences
Collection
[
|
...
]